GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (AMEX:PTN) » Definitions » Capex-to-Revenue

PTN (Palatin Technologies) Capex-to-Revenue : 0.00 (As of Sep. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Palatin Technologies Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Palatin Technologies's Capital Expenditure for the three months ended in Sep. 2024 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2024 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Palatin Technologies Capex-to-Revenue Historical Data

The historical data trend for Palatin Technologies's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palatin Technologies Capex-to-Revenue Chart

Palatin Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 - 0.18 0.09 0.01

Palatin Technologies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Palatin Technologies's Capex-to-Revenue

For the Biotechnology subindustry, Palatin Technologies's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Palatin Technologies's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palatin Technologies's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Palatin Technologies's Capex-to-Revenue falls into.



Palatin Technologies Capex-to-Revenue Calculation

Palatin Technologies's Capex-to-Revenue for the fiscal year that ended in Jun. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.043) / 4.49
=0.01

Palatin Technologies's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Palatin Technologies  (AMEX:PTN) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Palatin Technologies Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Palatin Technologies's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Palatin Technologies Business Description

Traded in Other Exchanges
Address
4B Cedar Brook Drive, Cranbury, NJ, USA, 08512
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Executives
Stephen T Wills officer: Executive Vice President, CFO PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Deveer Robert K Jr director C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Alan W Dunton director VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Carl Spana director, officer: President and CEO PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Joseph Stanley Hull director PALATIN TECHNOLOGIES INCORPORATED, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Arlene Morris director C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Anthony M. Manning director C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Angela Rossetti director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Robert I Taber director C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Zola P Horovitz director C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Perry B Molinoff director, officer: Exec. VP Research and Devel. C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104

Palatin Technologies Headlines

From GuruFocus